Cybersickness Prevention and Mitigation in Virtual Reality for Healthy Volunteers
Launched by NATIONAL HUMAN GENOME RESEARCH INSTITUTE (NHGRI) · Aug 12, 2024
Trial Information
Current as of July 21, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new software called Motion Reset, which aims to help reduce "cybersickness" in people who use virtual reality (VR). Cybersickness can feel similar to motion sickness, causing symptoms like dizziness, nausea, headaches, and eye strain after using VR. The researchers want to see if this software can make VR experiences more comfortable for users.
To participate, you need to be a healthy adult between the ages of 18 and 60 who can read, speak, and write in English. You should not have a history of severe motion sickness or certain medical conditions that could increase your chances of feeling sick in VR. Participants will have one visit to a clinic, where they will try out different VR experiences and answer questions about how they feel. The trial will include playing a popular VR game called Jurassic World Aftermath, during which you’ll be asked about any discomfort you may experience. This study is not currently recruiting participants, but if you meet the eligibility criteria, it could be a great opportunity to contribute to understanding how to make VR safer and more enjoyable for everyone.
Gender
ALL
Eligibility criteria
- * INCLUSION CRITERIA:
- In order to be eligible to participate in this study, an individual must meet all of the following criteria:
- • Provision of signed and dated informed consent form
- • Stated willingness to comply with all study procedures and availability for the duration of the study
- • Aged 18-60
- • Ability to read, speak, and write in English
- • Normal or corrected-to-normal hearing
- • Normal vision or corrected-to-normal without use of glasses. Contact lenses for corrective purposes are acceptable.
- • Ability to read, speak and write in English is a requirement because the VR-based study materials and assessment are only available in English and several of the key questionnaires for the study are not validated in other languages.
- EXCLUSION CRITERIA:
- An individual who meets any of the following criteria will be excluded from participation in this study:
- • Reporting motion sickness propensity of 0 or 10 on a 0-10 scale where 0 =never experience motion sickness and 10 = experience motion sickness very frequently (self-assessed by participants).
- • Reporting a history of photo-sensitive seizure disorders, vestibular disorders and/or other conditions that may make participants prone to nausea, dizziness, vertigo, ataxia, or incoordination.
- • Known pregnancy
- • Reporting current use of medication or supplements that inhibit nausea, e.g., Zofran/ondansetron, Phenergan/promethazine
About National Human Genome Research Institute (Nhgri)
The National Human Genome Research Institute (NHGRI) is a prominent research organization within the National Institutes of Health (NIH) dedicated to advancing the field of genomics and its applications in health and medicine. NHGRI sponsors and conducts a wide range of clinical trials aimed at understanding the genetic basis of diseases, developing innovative genomic technologies, and translating genomic research into clinical practice. With a commitment to ethical research and collaboration, NHGRI plays a pivotal role in shaping the future of personalized medicine and improving patient outcomes through genomic discoveries.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bethesda, Maryland, United States
Ames, Iowa, United States
Patients applied
Trial Officials
Susan J Persky, Ph.D.
Principal Investigator
National Human Genome Research Institute (NHGRI)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported